Author | Ian W. Flinn, MD, PhD | OncLive

Author | Ian W. Flinn, MD, PhD

Articles

Dr. Flinn on the Role of BTK Inhibitors in CLL

June 09, 2020

Video

Ian W. Flinn, MD, PhD, discusses the role of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Flinn on the Role of BTK Inhibitors in CLL

June 09, 2020

Video

Ian W. Flinn, MD, PhD, discusses the role of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Flinn on FDA Approval of Tisagenlecleucel in DLBCL

May 02, 2018

Video

Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of the chimeric antigen receptor T-cell therapy tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma.

Dr. Flinn on FDA Approval of Frontline Brentuximab Vedotin With AVD in Hodgkin Lymphoma

March 20, 2018

Video

Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of brentuximab vedotin (Adcetris) combined with Adriamycin, vinblastine, and dacarbazine (AVD) as a frontline treatment for patients with advanced classical Hodgkin lymphoma.

x